Skip to main content

Table 4 Prevalence of Pfcrt polymorphisms in paired pre-treatment and post-treatment samples in the artesunate-amodiaquine treatment arm, therapeutic efficacy monitoring, Mali, 2015 – 2016

From: Therapeutic efficacy of artemether–lumefantrine and artesunate–amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali, 20152016

  Pre-treatment n, (%)*
n = 26
Post-treatment n, (%)
n = 30
p-value**
Pfcrt point mutations    
Pfcrt codon 72
 C72 26 (100.0) 30 (100.0) NA
Pfcrt codon 73
 V73 26 (100.0) 30 (100.0) NA
Pfcrt codon 74
 M74 4 (15.4) 16 (53.3) 0.018
 74M/I 7 (26.9) 2 (6.7)  
 74I 15 (57.7) 12 (40.0)  
Pfcrt codon 75
 N75 4 (15.4) 16 (53.3) 0.018
 75N/E 7 (26.9) 2 (6.7)  
 75E 15 (57.7) 12 (40.0)  
Pfcrt codon 76
 K76 4 (15.4) 16 (53.3) 0.018
 76K/T 7 (26.9) 2 (6.7)  
 76T 15 (57.7) 12 (40.0)  
Pfcrt haplotypes
 CVIET 22 (84.6) 14 (46.7) 0.082
 CVMNK 11 (42.3) 18 (60.0)  
  1. Bold letter denotes an encoded amino acid change
  2. Haplotype totals include mixed infections
  3. *4 recrudescent infections not included
  4. ** Comparing wild-type vs. mutant (excluding mixed infections) for point mutations and CVIET versus CVMNK haplotypes